9 December 2019 - Oral GLP-1 semaglutide achieves commonly cited thresholds for cost-effectiveness but is less cost-effective than SGLT-2 competitor empagliflozin.

Independent appraisal committee votes that oral semaglutide provides a superior net health benefit over background therapy alone, achieves intermediate long-term value for money, and may be an attractive alternative for patients who would prefer an oral treatment; however, the large potential short-term budget impact associated with treating even a small percentage of eligible US patients leads ICER to issue an Access and Affordability Alert.

The Institute for Clinical and Economic Review today released a final evidence report and Report-at-a-Glance assessing the comparative clinical effectiveness and value of oral semaglutide (Rybelsus, Novo Nordisk), a GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus.

Read ICER Announcement